Clinical Cardiology Alert – August 1, 2010
August 1, 2010
View Issues
-
'Bleeding Avoidance Strategies' and PCI
Access-site bleeding is one of the major complications of percutaneous coronary intervention (PCI). It is associated with the need for blood transfusions, increased length of stay, and increased healthcare expenditure. -
Bleeding with Dual-antiplatelet Therapy
Dual-antiplatelet therapy with aspirin and clopidogrel is recommended for patients with known vascular disease or multiple risk factors for vascular disease. However, little is known about the long-term bleeding risk of such therapy. -
Performance of a Bleeding-risk Score
The can rapid-risk stratification of unstable angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) is a registry study of acute coronary-syndrome patients. -
Management of Antithrombotic Therapy with Device Placement
Many patients who receive pacemakers or implantable cardioverter defibrillators (ICDs) are chronically treated with antiplatelet agents, warfarin, or a combination of the two. In this paper, Tompkins and colleagues from the Johns Hopkins Hospital report the results of a retrospective review of antiplatelet and anticoagulant management in patients receiving cardiac-rhythm devices. -
Left Main PCI vs. CABG: Five-year Follow-up of Two Registries
The evolution of percutaneous coronary intervention (PCI) techniques has resulted in PCI becoming a reasonable alternative to coronary artery bypass graft (CABG) surgery in selected patients with unprotected left-main coronary artery (ULMCA) stenosis. -
Management of Recalled ICD Leads
The Medtronic Sprint-Fidelis ICD-lead family is associated with an increased risk for lead fracture. -
Exercise Training for POTS
Postural orthostatic tachycardia syndrome (POTS) is a disabling orthostatic intolerance that mainly occurs in pre-menopausal women. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Aggressive approach to CVD reduces MI, folic acid and vitamin B12 for CAD, corticosteroids for acute exacerbations of COPD, prescription drug abuse among young adults, and ARBs and cancer risk.